Skip to Content
Cancer Diagnosis Program (CDP) — Biorepositories & Biospecimen Research Branch (BBRB) Cancer Diagnosis Program (CDP) Biorepositories & Biospecimen Research Branch (BBRB)
Contact NExT
Show menu
Search this site
Last Updated: 09/14/23

Past Funding Opportunities

Cancer Moonshot Biobank Biospecimen Core Resource RFP

In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., has issued Requests for Proposals for a Biospecimen Core Resource (BCR). The BCR will have responsibility for shipment of biospecimen collection kits; receipt of biospecimens; processing specimens (e.g. histological sectioning, staining, imaging) for pathology review; storage and tracking of biospecimens; extraction of nucleic acids; and shipment of biospecimens and their derivatives to appropriate laboratories and researchers.

Questions due 2/21/19; Bidder’s teleconference 2/28/19; Proposals due 3/18/19.

https://frederick.cancer.gov/workwithus/solicitations/s19-054

Cancer Moonshot Biobank Patient and Provider Engagement (PPE) Portal RFP

In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., has issued Requests for Proposals for a Patient and Provider Engagement (PPE) Portal. This effort will develop and deploy a web portal that meets the needs of patients, their family members, their healthcare providers, and medical institutions. The PPE portal will have an open access site to allow anyone learn about the project and will also have a secure section for authenticated users.

Questions due 2/15/19; Bidder’s teleconference 3/21/19; Proposals due 4/8/19.

https://frederick.cancer.gov/workwithus/solicitations/s19-053

Cancer Moonshot Biobank e-consent RFP

In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., has issued Requests for Proposals for an electronic informed consent tool to allow participants at up to 150 different sites to electronically consent to participate in the Cancer Moonshot Biobank project. The eConsent tool will be accessed with a standard web browser on the world wide web.

https://frederick.cancer.gov/workwithus/solicitations/s19-003

Cancer Moonshot Biobank Biospecimen Source Site Coordinator (BSSC) RFP

In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., has issued Requests for Proposals for a Biospecimen Source Site Coordinator (BSSC) who will be responsible for training, coordinating, and assisting Biospecimen Source Sites (BSSs). The BSSC will provide reimbursement to the BSSs for biospecimen and data acquisition as well as other activities as needed.

https://frederick.cancer.gov/workwithus/solicitations/s18-087

Cancer Moonshot Biobank Project - Institutional Review Board (IRB)

In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., seeks a subcontractor to carry out the IRB review requirements as specified under the Health and Human Services (HHS) regulations at 45 Code of Federal Regulations (CFR) part 46. There are two main tasks required for this project: 1) to serve as a single IRB for up to 150 participating Biospecimen Source Sites (BSS), and 2) to serve as the IRB for the Biospecimen Core Resource (BCR). Proposal Due Date: Wednesday, September 5, 2018.

https://frederick.cancer.gov/workwithus/solicitations/s18-095

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)

PAR-16-166

Posted date: April 5, 2016; Expiration date: June 23, 2017
Application receipt dates: June 22, 2016; February 13, 2017; October 11, 2017; June 22, 2018, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development due to preanalytical variability in tissue biopsy biospecimens. The program will tie in with current efforts to optimize clinical biomarker assays utilized in NCI-sponsored clinical trials. Results from this research program will improve the understanding of how biopsy collection, processing, and storage procedures may affect assay detection limits for current and emerging clinical biomarkers, as well as expedite clinical biomarker assay development through the evidence-based standardization of biopsy handling practices.

The FOA will fund multidisciplinary teams that will constitute a collaborative network using a U01 Cooperative Agreement. Each team's application will focus on specific biomarker assays and associated questions in biospecimen science, and present a research plan for acquiring the needed biospecimens. Multidisciplinary scientific teams will be involved, including pathologists, oncologists, radiologists, molecular biologists, and statisticians, as the work requires expertise and perspectives in clinical medicine, knowledge of the unique issues related to obtaining biopsy biospecimens, biology and technology platforms, and experimental design and analysis. These teams must include investigators currently involved in NCI Phase I and Phase II clinical trials. Projects will involve defining workable biospecimen conditions for trials that utilize a particular type of biopsy (e.g. lung aspirates, liver biopsies) in a biomarker assay system (e.g. NGS for mutation-targeted drug trials; multi-analyte IHC/IFA or targeted mass spec for PD assays/pathway analysis) to detect emerging clinical biomarkers.

https://grants.nih.gov/grants/guide/pa-files/PAR-16-166.html

CDP contact: Dr. Abhi Rao, 240-276-5715, abhi.rao@mail.nih.gov